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Background: Wolfram Syndrome type 2 (WFS2) is considered a phenotypic and genotypic variant of WFS, whose
minimal criteria for diagnosis are diabetes mellitus and optic atrophy. The disease gene for WFS2 is CISD2. The
clinical phenotype of WFS2 differs from WFS1 for the absence of diabetes insipidus and psychiatric disorders,
and for the presence of bleeding upper intestinal ulcers and defective platelet aggregation. After the first report
of consanguineous Jordanian patients, no further cases of WFS2 have been reported worldwide. We describe the
first Caucasian patient affected by WFS2.
Case presentation: The proband was a 17 year-old girl. She presented diabetes mellitus, optic neuropathy,
intestinal ulcers, sensorineural hearing loss, and defective platelet aggregation to ADP. Genetic testing showed a
novel homozygous intragenic deletion of CISD2 in the proband. Her brother and parents carried the heterozygous
mutation and were apparently healthy, although they showed subclinical defective platelet aggregation. Long runs
of homozygosity analysis from SNP-array data did not show any degree of parental relationship, but the microsatellite
analysis confirmed the hypothesis of a common ancestor.
Conclusion: Our patient does not show optic atrophy, one of the main diagnostic criteria for WFS, but optic
neuropathy. Since the “asymptomatic” optic atrophy described in Jordanian patients is not completely supported, we
could suppose that the ocular pathology in Jordanian patients was probably optic neuropathy and not optic atrophy.
Therefore, as optic atrophy is required as main diagnostic criteria of WFS, it might be that the so-called WFS2 could
not be a subtype of WFS. In addition, we found an impaired aggregation to ADP and not to collagen as previously
reported, thus it is possible that different experimental conditions or inter-patient variability can explain different results
in platelet aggregation. Further clinical reports are necessary to better define the clinical spectrum of this syndrome
and to re-evaluate its classification.
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Wolfram syndrome (WFS; MIM 222300) is a rare neuro-
degenerative disease with autosomal recessive inheritance
and incomplete penetrance, whose diagnosis requires dia-
betes mellitus (DM) and optic atrophy (OA). WFS in-
cludes a wide spectrum of other possible disorders, such
as diabetes insipidus, sensorineural deafness, genitourinary
tract problems, male hypogonadism, neurological or psy-
chiatric disorders, and less frequently, bowel dysfunction.
Clinical wide spectrum is likely sustained by a genetic het-
erogeneity [1]. To date, 2 types of WFS, type 1 (WFS1;
MIM 606201) and type 2 (WFS2; MIM 604928) charac-
terized by different disease genes have been identified.
The disease gene for WFS2 is CISD2, encoding for a
highly conserved zinc-finger protein of the Endoplasmic
Reticulum Intermembrane Small (ERIS), playing a pivotal
role in calcium homeostasis (Ca2H) [2]. It was identified
in three consanguineous Jordanian families carrying a
point mutation in exon 2 [3]. In WFS2, diabetes insipidus
and psychiatric disorders are not described, whereas
bleeding upper intestinal ulcers (b-UIU), not reported in
WFS1 [4], and defective platelet aggregation (PA) may be
considered diagnostic criteria. After the first report [3,5],
no further CISD2 mutations have been reported. We de-
scribe the first Caucasian patient with WFS2 with a novel
homozygous CISD2 intragenic deletion.
Case presentation
Our patient was a Caucasian girl (FS), first child of non-
consanguineous parents. Since the age of 5 years old, FS
suffered from recurrent b-UIU. When 14 years old, mal-
rotation and partial duodenum intussusception were
diagnosed, resection of a duodenal tract and duodenal-
jejunal anastomosis were performed. At the age of 16,
she suffered from reduced visual acuity and dyschroma-
topsia, so she underwent eye examination including
BCVA (20/40 in the right and 20/50 in the left eye), slit
lamp biomicroscopy (normal anterior segment bilat-
erally), fundus examination (optic disc pallor with pre-
served pupillary light reflexes bilaterally), and p-VEP
according to the ISCEV guidelines [6], (normal latency
and normal amplitude responses bilaterally). The b-MRI
showed normal optic nerve caliber in both eyes. At 17
years old non-autoimmune diabetes occurred and WFS2
was suspected. She started insulin treatment. Further ex-
aminations showed a bilateral sensorineural hearing loss
in the high frequencies (SHLHF), and a slow intestinal
transit time with entero-gastric bile reflux (EGBR). As
visual acuity, pupillary light reflexes, slit lamp biomicro-
scopy, fundus examination and p-VEP were unchanged
after 5 years follow up, additional eye exams were per-
formed in order to extensively define optic nerve in-
volvement. Visual field testing, ERG, MP, and OCT of
macula and retinal nerve fiber layer showed a moderateinvolvement of the optic nerve in both eyes, compatible
with a diagnosis of Optic Neuropathy (ON), excluding
the OA (Figure 1) and other ocular abnormalities.
Evaluating PA, a reduced and reversible defective PA
up to 10 μM of ADP was present, whereas PA in response
to other tested agents (collagen, epinephrine, ristocetin)
was within normal ranges. Platelet secretion in response
to ADP was absent (Figure 2). The bleeding score, accord-
ing to Tosetto et al. [7], was 3 (normal values: ≤3), the
other main coagulative tests were normal.
Ophtalmological abnormalities, DM and deafness were
not found in the parents and brother, whereas a revers-
ible PA in response to ADP was found. Currently, FS is
22 years old and presents DM, ON with preserved visual
acuity and electrophysiologic tests, no OA, tinnitus due
to SHLHF triggered by loud environments, EGBR, slow
intestinal transit, reduced and reversible defective PA to
ADP, and b-UIU.Matherials and methods
DNA from the proband, parents, brother and controls
were extracted from whole blood using High Pure PCR
Template Preparation Kit (Roche, Mannheim, Germany).
The three exons and the flanking region of CISD2 gene
were amplified by PCR (PrimeStar GXL DNA Polymerase,
Takara Bio Inc, Japan) using three couples of primers.
Amplicons were purified and then sequenced for both
sense and antisense strands. CISD2 cDNA sequencing
was performed using known cDNA primers and condi-
tions [3]. SNP-array analysis on trios was performed using
the Affymetrix CytoScan HD Array (Affymetrix, Santa
Clara, CA) as previously described [8].
Patients were enrolled after obtaining appropriate in-
formed consent and approval by the local ethics commit-
tee (#08-CE) of the IRCCS Casa Sollievo della Sofferenza
(San Giovanni Rotondo) where genetics studies were car-
ried out.Identification of novel mutation in CISD2
In the patient the amplification of CISD2 exon 2 was not
detected, while exons 1 and 3 were regularly present.
Moreover exons 1, 2 and 3 were amplified in parents, in
brother and in controls. CISD2 cDNA sequencing re-
vealed a novel homozygous deletion affecting the whole
exon 2 of CISD2 (see Additional file 1: Figure S1). To
further confirm the exon 2 deletion, to map boundaries,
and to confirm that her parents and brother were car-
riers, a SNP-array analysis on trios was performed. Log2-
Ratio values of markers encompassing the CISD2 deletion
were of approximately -0.45 to -1, suggestive for a het-
erozygous deletion (mother, father and brother) while
Log2Ratio values from -1 to higher negative values were
suggestive for homozygous deletion.
Figure 1 The figure displays the results of ocular investigations. a) Fundus ocular examination showing slight pallor of optic disc in both
eyes, associated with best corrected visual acuity (BCVA) of 20/40 in the right eye and 20/50 in the left eye. b) Optical coherence tomography
(OCT) retinal nerve fiber layer showing a moderate suffering of superior and inferior axonal fibers of optic nerve in both eyes and of nasal axonal
fibers in the left eye. c) Visual field testing showing reduced retinal sensitivity in the temporal-inferior sector starting from the blind spot in the
right eye and a generalized reduced retinal sensitivity reaching the nasal-inferior sector towards 30° in the left eye. The pattern visual evoked
potentials (picture not shown) showed normal latency and normal amplitude responses in both eyes (latencies < 100 ms; amplitude of 6.2 μV in
right eye and 5.9 μV in left eye [range of normal values 5.8 – 6.2 μV]).
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Figure 2 The figure displays the platelet aggregation and secretion in response to ADP at different concentrations: 2 mM L−1 (left panel),
4 mM L−1 (central panel) 10 mM L−1 (right panel). In the lower part of each figure, the wave corresponds to ATP secretion from platelets.
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(102,885,416 bp) to C-6MGSK (102,886,154 bp), which
were the first and the last deleted oligonucleotide from the
centromere, respectively (Table 1). The minimum size of
deletion was 739 bp while the maximum size was 4,250 bp.
Combining these data with the ones from PCR, we were
able to map the proximal breakpoint (centromeric) be-
tween the last present probe C-4JSGI (102,885,132 bp) and
the first deleted probe C-4OKFJ (102,885,416 bp), while
the distal breakpoint (telomeric) between the last de-
leted probe C-6MGSK (102,886,154 bp) and the forward
amplification oligo of CISD2 exon 3 (from 102,887,186
to 102,887,207 bp). Thus, the maximum deletion size
has been restricted to a region of 2,050 bp spanning
from intron 2 to intron 3. Base pair position were
derived from the University of California Santa Cruz
(UCSC) Genome Browser (http://genome.ucsc.edu/cgi-
bin/hgGateway), build GRCh38 (Figure 3). The max-
imum deletion size was restricted to a region of 2,050 bp
spanning from intron 2 to intron 3. The deletion was
homozygous in the proband and heterozygous in her par-
ents and brother. Since the mutation had never been re-
ported, consanguinity was hypothesized. The patient’s
parents reported to be not consanguineous even if their





4 102,885,132 C-4JSGI 0.493916
4 102,885,416 C-4OKFJ −33.194.1
4 102,885,416 C-3IWPX −32.682.1
4 102,885,641 C-6VJTI −43.055.0
4 102,886,154 C-6MGSK −1.749.2
4 102,889,381 C-4SDGK −0.023144where they are still living. Long runs of homozygosity
analysis from SNP-array data did not show any degree
of parental relationship. The percentage of estimate
consanguinity expressed in term of Coefficient of Inbree-
deing was calculated as reported in Kearney et al. [9]
(Table 2). Microsatellite analysis confirmed the hypothesis
of a common ancestor (data not shown).
Discussion
We describe the first European Caucasian girl with WFS2,
carrying a novel intragenic exon 2 CISD2 homozygous de-
letion. Only a homozygous mutation of the CISD2, a sin-
gle nucleotide substitution that leads to a missense change
Glu37Gln, was previously associated to WFS2 [3]. This
gene, mapping on chromosome 4q24 [1], encodes an ex-
tremely small zinc-finger protein, named ERIS, which dis-
plays a fairly wide cellular expression profile, including
pancreas, brain, blood and platelets [3]. Conlan et al. [10]
showed that the domain 2Fe-2S is essential for the activity
of this zinc-finger protein, and is located from aminoacid
99 (Cys) to aminoacid 112 (Gly). Genomic data from our
subjects show that the triplets coding for aminoacids
WRSKT, from the position 102 to 106 of the polypeptide,
are within the deleted region, and this may result in a non
functional protein because of zinc-finger domain lost. Thedeletion on the CytoScan HD array
Log2 Ratio
t Brother Father Mother
75 0.67028916 0.31938627 0.7485791
53 −0.6410765 −0.6913735 −0.86971235
35 −0.6565456 −0.35076097 −0.6521124
53 −10.099.052 −0.98227024 −17.431.074
46 −0.5463655 −12.236.409 −0.75301945
266 −0.23841621 0.05294265 0.06327062
Figure 3 Schematic representation of CISD2 gene and of the deleted region. Black arrows represent PCR primers, unfilled triangles undeleted
probes while filled triangles deleted probes. Line 1 represent the size of the deletion obtained by combining array and PCR data, line 2 and line 3
respectively the maximum size of the deletion and the minimum size of the deletion based on array results. On the upper line the coordinates of the
region in hg38.
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82% similarity across all the vertebrate species [3]. It plays
a pivotal role in Ca2H [2], as well as wolframin, another
endoplasmic reticulum (ER) [7] protein encoded by WFS1
gene. Also wolframin is involved in the regulation of ER
stress and Ca2H [11,12], without any interaction with
ERIS. The ER function influences some crucial secretory
proteins, such as insulin, as well as cell-surface receptors
and integral membrane proteins. Imbalance in Ca2H of
ER elicits stress in this organelle, leading to the accumula-
tion of misfolded and unfolded protein in the organelle, a
state called ‘ER stress’, which plays, in WFS, a key role in
β-cells, leaving these cells more prone to oxidative stress
and consequently to apoptosis. Activation of the unfolded
protein response (UPR), an adaptive response that coun-
teracts the ER stress, serves to restore ER homeostasis.
Moreover, UPR maintains pancreatic β-cell function and
promotes β-cell survival. Exaggerated ER stress, which
normally triggers the UPR, has been hypothesized in the
β-cells impairing the cell progression and increasing apop-
tosis [13]. Neuronal cells have highly developed ER, whose
"stress" is related with ganglion cells apoptosis, as demon-
strated in a glaucoma chronic injury model [14]. The de-
generation of ganglion and glial retinal cells could be
related to the ER stress probably accountable for the ocu-
lar involvement in our patient that presented moderate
ON but not OA. Few and non-specific studies on ERISTable 2 The percentage of estimate consanguinity
expressed in term of Coefficient of Inbreedeing and
Identical by Descent [9]
Coefficient of inbreeding IBD (Identical by Descent %)
Patient 0.0086908 0.86
Brother 0.002465 0.24localization and expression, in particular in the ganglion
and glial cells of the optic nerve, may explain the different
optic nerve involvement and a favourable outcome of ocu-
lar pathology. In WFS1, early OA causes alterations of the
optic nerve caliber due to the loss of a considerable num-
ber of ganglion cells [15]. These patients show severe pro-
gressive visual acuity reduction and non recordable p-VEP
or increased latency or greatly reduced amplitudes [16,17].
In Jordanian WFS2 patients OA was observed after child-
hood or was described as “asymptomatic”, but opportune
investigations were not reported [1]. Since our patient
does not show OA at the age of 22 years, and since
“asymptomatic” OA described in Jordanians is not com-
pletely supported, we suppose that the ocular pathology in
those patients was probably ON and not OA. This is just
a case report and thus great caution is needed, even if the
absence of OA, one of the main diagnostic criteria of
WFS, suggests that the so-called WFS2 could not be a
WFS subtype.
As shown in Table 3 the clinical spectrum of WFS1
and WFS2 is only partially coincident, according to the
different expression of the two proteins. In fact wolfra-
min is expressed in pancreas, brain, heart, skeletal
muscle, placenta, lung, liver and kidney, while ERIS is
expressed in pancreas, brain, blood and platelets. Fur-
thermore in WFS2 patients, diabetes insipidus and psy-
chiatric disorders are not described so far, otherwise
some additional features are present and may be consid-
ered diagnostic criteria: significant bleeding tendency,
defective PA with collagen [4], and peptic ulcer disease
with b-UIU [5]. The tendency to mucocutaneous bleed-
ings mainly displayed by gastric ulcers is a common fea-
ture, observed in 79% and 90% respectively of Jordanian
patients [5]. Expression studies using mass spectrom-
etry listed in the Human Protein Reference Database
Table 3 Clinical features of WFS1, WFS2, and of our case
Clinical features WFS 1 WFS2 WFS2 our case
Diabetes mellitus X X X
Optic atrophy X X
Sensorineuronal Deafness X X X
Diabetes Insipidus X
Neurological and Psychiatric disorders X
Genitourinary tract problems X
Male hypogonadism X
Bowel disfunction X X
Upper intestinal ulcers X X
Platelet aggregation defects to collagen X
Platelet aggregation defects to ADP X
Optic neuropathy X
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transcripts in platelets [3]. This may explain, at least in
part, the bleeding phenotype [18] described in these
patients.
Furthermore, in Table 3 we show the difference in the
clinical spectrum of Jordanian cases [1] and our patient.
Firstly, our girl presented ON and not OA even though as
previously discussed it is possible that the ocular path-
ology in those patients was probably ON and not OA;
secondly, she showed an impaired platelet aggregation to
ADP and not to collagen; however collagen- and ADP-
induced aggregation are both calcium-mediated, thus it is
possible that different experimental conditions or inter-
patient variability can explain different results in PA.
The new findings of this report could better characterize
the WFS2 phenotype.
Conclusion
We describe the first Caucasian patient with so-called
WFS2. She carried a novel mutation in CISD2. Our data
debate the previous description of WFS2 pointing out
new data about eye and platelets involvement. The pro-
band presented optic neuropathy and not optic atrophy,
impaired platelet aggregation to ADP and not to colla-
gen. Further clinical reports are necessary to better
define the clinical spectrum of this syndrome and to re-
evaluate its classification.
Consent
This study was approved by institutional ethics committee
and was done in accordance with Declaration of Helsinki.
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the study participants. Moreover, as the patient is a girl,
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for publication of this Case report. A copy of the written
consent is available for review by the Editor of this
journal.Additional file
Additional file 1: Figure S1. The upper part of the figure displays the
PCR amplification of CISD2 exons: agarose electrophoresis shows no exon
2 detection in proband (p) DNA. The lower part displays CISD2 cDNA PCR
amplification: agarose electrophoresis shows absence of proband (p)
CISD2 cDNA. From the left to the right: f: father, m: mother, p: proband,
b: brother, ct+ ct-: controls, MW: molecular weight.
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